Skip Navigation


Annals of Oncology Advance Access originally published online on March 6, 2006
Annals of Oncology 2006 17(4):623-629; doi:10.1093/annonc/mdj130
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/4/623    most recent
mdj130v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baweja, M.
Right arrow Articles by Perez, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baweja, M.
Right arrow Articles by Perez, E. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients ≥65 years of age: an NCCTG study

M. Baweja1, V. J. Suman2, T. R. Fitch3, J. A. Mailliard4, A. Bernath5, K. M. Rowland6, S. R. Alberts2, J. S. Kaur2 and E. A. Perez1,*

1 Mayo Clinic, Jacksonville, FL; 2 Mayo Clinic, Rochester, MN; 3 Mayo Clinic, Scottsdale, AZ; 4 Missouri Valley Cancer Consortium CCOP, Omaha, NE; 5 Geisinger Medical Center, Danville, PA; 6 Carle Cancer Center, Urbana, IL, USA

* Correspondence to: Dr E. A. Perez, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Tel: +1904-953-7283; Fax: +1904-953-2315; E-mail: perez.edith{at}mayo.edu

Background: A one-stage phase II trial was conducted to assess the tumor response rate and toxicity profile of single agent oral vinorelbine as first or second-line chemotherapy for women at least 65 years of age with metastatic breast cancer.

Patients and methods: Twenty-five patients with metastatic breast cancer aged ≥65 years of age were enrolled to receive oral vinorelbine on a weekly basis. The oral vinorelbine was given at 60 mg/m2 weekly for the first four doses and was increased to 70 mg/m2 for the subsequent administrations if there was no grade 4 neutropenia or no more than one episode of grade 3 neutropenia. Therapy was continued until progression or intolerable toxicity.

Results: Twenty-five patients were included and evaluable for analysis. One patient (4%) achieved a partial response (PR) that lasted for more than 13 months. Two additional patients remained stable for at least 6 months for a clinical benefit rate (PR + stable disease) of 12%. The 1-year survival rate was estimated to be 48% (95% CI 30% to 74.5%). Median time to progression was estimated to be 4.7 months (95% CI 2.0–5.5 months) and the 9-month disease progression-free rate was estimated to be 8% (95% CI 30.9% to 74.5%). The treatment was fairly well tolerated with grade 3 neutropenia in 12.5%, fatigue in 12.5% of the patients, and grade 2 neuromotor and neurosensory toxicities in 12.5% and 8.3%, respectively.

Conclusion: Oral vinorelbine as a single agent at these dose and schedule in this population of women ≥65 years is well tolerated but has a low level of objective efficacy for the treatment of metastatic breast cancer.

Key words: elderly, metastatic breast cancer, vinorelbine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Findlay, G. von Minckwitz, and A. Wardley
Effective oral chemotherapy for breast cancer: pillars of strength
Ann. Onc., February 1, 2008; 19(2): 212 - 222.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.